Hearing Loss Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Hearing Loss pipeline constitutes 32+ key companies continuously working towards developing 35+ Hearing Loss treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Hearing Loss Overview
Hearing loss is the partial or complete loss of hearing in one or both ears, ranging from mild to profound. There are many causes, and it can affect anyone at any age, but it's most common in people older than 60. Hearing loss in older adults is known medically as presbycusis.

"Hearing Loss Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hearing Loss Market.

The Hearing Loss Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hearing Loss Pipeline Report: https://www.delveinsight.com/report-store/hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Hearing Loss treatment therapies with a considerable amount of success over the years. Hearing Loss Key players such as - Acousia Therapeutics, Frequency Therapeutics, Acousia Therapeutics, Decibel Therapeutics, Otonomy, Inc., Pipeline Therapeutics, AudioCure Pharma GmbH, Frequency Therapeutics, Sensorion, and others, are developing therapies for the Hearing Loss treatment
• Hearing Loss Emerging therapies such as - ACOU 082, FX-345, ACOU085, DB-020, OTO 413, PIPE 505, AC102, FX-322, SENS-401, and others are expected to have a significant impact on the Hearing Loss market in the coming years.
• SENS-401 has been granted Orphan Drug Designation by the EMA in Europe for the treatment of sudden sensorineural hearing loss, and by the FDA in the U.S. for the prevention of platinum-induced ototoxicity in pediatric population
• In January 2023, Sensorion announces that the first patient has been enrolled in its Phase 2a Proof of Concept clinical trial ofSENS-401 (Arazasetron) in patients suffering from Cisplatin-Induced Ototoxicit
• In February 2023, Frequency Therapeutics, Inc. announced clinical results from the placebo-controlled Phase IIb study of FX-322 in individuals with acquired Sensorineural Hearing Loss (SNHL). Data showed no statistically meaningful difference at day 90 between those administered FX-322 versus those receiving placebo in the proportion of individuals that demonstrated an improvement in speech perception
• In August 2022, Sensorion initiated a Phase II a, open-label, randomized and controlled study investigating repeated twice-daily administration of oral SENS-401 in adult participants with moderately severe to profound hearing loss who have already agreed to undergo cochlear implant surgery justified by their hearing impairment
• In October 2022, Otonomy, Inc., announced that the clinical evaluation of higher doses for OTO-413 (0.75 mg and 1.50 mg) in patients with hearing loss demonstrated no clinically meaningful improvement for patients from baseline across multiple speech-in-noise (SIN) hearing tests

Route of Administration
Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Hearing Loss Pipeline Therapeutics Assessment
• Hearing Loss Assessment by Product Type
• Hearing Loss By Stage and Product Type
• Hearing Loss Assessment by Route of Administration
• Hearing Loss By Stage and Route of Administration
• Hearing Loss Assessment by Molecule Type
• Hearing Loss by Stage and Molecule Type

DelveInsight's Hearing Loss Report covers around 35+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Hearing Loss Drugs Under Different Phases of Clinical Development Include:
• ACOU 082: Acousia Therapeutics
• SENS-401: Sensorion
• ACOU085: Acousia Therapeutics
• OTO-413: Otonomy Inc.
• DB-020: Decibel Therapeutics
• FX-345: Frequency Therapeutics
• ACOU085: Acousia Therapeutics
• DB-020: Decibel Therapeutics
• OTO 413: Otonomy, Inc.
• PIPE 505: Pipeline Therapeutics
• AC102: AudioCure Pharma GmbH
• FX-322: Frequency Therapeutics
• SENS-401: Sensorion

Get a Free Sample PDF Report to know more about Hearing Loss Pipeline Therapeutic Assessment
https://www.delveinsight.com/sample-request/hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hearing Loss Pipeline Analysis:
The Hearing Loss pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hearing Loss with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hearing Loss Treatment.
• Hearing Loss key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hearing Loss Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hearing Loss market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Hearing Loss product details are provided in the report. Download the Hearing Loss pipeline report to learn more about the emerging Hearing Loss therapies
https://www.delveinsight.com/sample-request/hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hearing Loss Pipeline Market Drivers
• Rapidly growing incidence of acute sensorineural hearing loss
• Rise in geriatric population

Hearing Loss Pipeline Market Barriers
• Challenges associated with the delivery of therapeutics for Sensorineural Hearing Loss
• Poor understanding of the specific underlying pathologies

Scope of Hearing Loss Pipeline Drug Insight
• Coverage: Global
• Key Hearing Loss Companies: Acousia Therapeutics, Frequency Therapeutics, Acousia Therapeutics, Decibel Therapeutics, Otonomy, Inc., Pipeline Therapeutics, AudioCure Pharma GmbH, Frequency Therapeutics, Sensorion, and others
• Key Hearing Loss Therapies: ACOU 082, FX-345, ACOU085, DB-020, OTO 413, PIPE 505, AC102, FX-322, SENS-401, and others
• Hearing Loss Therapeutic Assessment: Hearing Loss current marketed and Hearing Loss emerging therapies
• Hearing Loss Market Dynamics: Hearing Loss market drivers and Hearing Loss market barriers

Request for Sample PDF Report for Hearing Loss Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Hearing Loss Report Introduction
2 Hearing Loss Executive Summary
3 Hearing Loss Overview
4 Hearing Loss- Analytical Perspective In-depth Commercial Assessment
5 Hearing Loss Pipeline Therapeutics
6 Hearing Loss Late Stage Products (Phase II/III)
7 Hearing Loss Mid Stage Products (Phase II)
8 Hearing Loss Early Stage Products (Phase I)
9 Hearing Loss Preclinical Stage Products
10 Hearing Loss Therapeutics Assessment
11 Hearing Loss Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Hearing Loss Key Companies
14 Hearing Loss Key Products
15 Hearing Loss Unmet Needs
16 Hearing Loss Market Drivers and Barriers
17 Hearing Loss Future Perspectives and Conclusion
18 Hearing Loss Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Hearing Loss drugs and therapies https://www.delveinsight.com/sample-request/hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports-
Hearing Loss Epidemiology https://www.delveinsight.com/report-store/hearing-loss-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hearing Loss Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Related Reports By DelveInsight -

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.